Company · CIK 0001833141 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
CYBIN INC. · CYBN
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 21, 2026 PForm 4 → | Sep 21, 5:07 pm EDT | Michael HalsteadChief Executive Officer | 100,000 | $13.47 | $1,347,050 | 168,568 | +146% | |
| Sep 8, 2026 PForm 4 → | Sep 11, 9:04 am EDT | Paul GlavineChief Growth Officer | 100,000 | $12.47 | $1,247,190 | 4,271,252 | +2.40% | late |
| Sep 8, 2026 PForm 4 → | Sep 11, 9:03 am EDT | Paul GlavineChief Growth Officer | 100,000 | $12.47 | $1,247,190 | 4,271,252 | +2.40% | late |
| Sep 8, 2026 PForm 4 → | Sep 11, 9:01 am EDT | Eric H. L. SoExecutive Chair, Director | 100,000 | $12.39 | $1,238,670 | 4,465,014 | +2.29% | late |
| Sep 4, 2026 PForm 4 → | Sep 10, 6:21 am EDT | Eric H. L. SoExecutive Chair, Director | 100,000 | $12.09 | $1,208,900 | 4,365,014 | +2.34% | late |
| Sep 3, 2026 PForm 4 → | Sep 10, 6:19 am EDT | Paul GlavineChief Growth Officer | 100,000 | $11.78 | $1,178,280 | 4,171,252 | +2.46% | late |
| Sep 1, 2026 PForm 4 → | Sep 9, 5:47 pm EDT | Eric H. L. SoExecutive Chair, Director | 95,000 | $11.81 | $1,121,475 | 4,265,014 | +2.28% | late |
| Aug 31, 2026 PForm 4 → | Sep 9, 11:03 am EDT | Paul GlavineChief Growth Officer | 90,000 | $11.59 | $1,042,677 | 4,071,252 | +2.26% | late |
Reported at this company — derivatives (options, RSUs, warrants)
No reported derivative activity in this period.